Morabito, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 205
EU - Europa 169
AS - Asia 107
SA - Sud America 31
AF - Africa 3
Totale 515
Nazione #
US - Stati Uniti d'America 203
SE - Svezia 57
SG - Singapore 44
IT - Italia 32
BR - Brasile 28
IN - India 25
CN - Cina 19
IE - Irlanda 19
FR - Francia 18
DE - Germania 16
ID - Indonesia 9
GB - Regno Unito 6
KR - Corea 6
RU - Federazione Russa 6
AR - Argentina 3
AT - Austria 3
MA - Marocco 3
PL - Polonia 3
NL - Olanda 2
AM - Armenia 1
BE - Belgio 1
CA - Canada 1
CZ - Repubblica Ceca 1
FI - Finlandia 1
GR - Grecia 1
IR - Iran 1
LK - Sri Lanka 1
MX - Messico 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
Totale 515
Città #
Chandler 53
Singapore 35
New York 22
Ashburn 21
Hyderabad 19
Dublin 13
Florence 9
Jakarta 9
Düsseldorf 7
Marseille 6
Milan 6
Princeton 6
San Mateo 6
Seoul 6
Hefei 5
Wilmington 5
Frankfurt am Main 4
Genoa 4
Nuremberg 4
Pune 4
Vicopisano 4
Boston 3
Falls Church 3
Lauterbourg 3
Los Angeles 3
Norwalk 3
São Paulo 3
Wroclaw 3
Belo Horizonte 2
Brooklyn 2
Buenos Aires 2
Cattolica 2
Fairfield 2
Fremont 2
Garden City 2
Houston 2
London 2
Moscow 2
Portsmouth 2
Turin 2
Verona 2
Washington 2
Agua Prieta 1
Andover 1
Aparecida de Goiânia 1
Arapiraca 1
Araraquara 1
Ashgabat 1
Athens 1
Beijing 1
Blumenau 1
Bratislava 1
Brockton 1
Brussels 1
Caracal 1
Caseros 1
Catanduva 1
Charleston 1
Chicago 1
Colombo 1
Columbus 1
Conceição do Coité 1
Fes 1
Goiânia 1
Gurgaon 1
Helsinki 1
Kish 1
Lisbon 1
Lorena 1
Manchester 1
Morungaba 1
Nador 1
Niterói 1
Padova 1
Paris 1
Parma 1
Pomigliano D'arco 1
Porto Acre 1
Prague 1
Presidente Venceslau 1
Redwood City 1
Ribeirão Preto 1
Ribeirão das Neves 1
Rudrapur 1
Russas 1
Saint Petersburg 1
Salvador 1
Santana do Livramento 1
Seattle 1
Secaucus 1
São Gabriel 1
São José 1
São José da Coroa Grande 1
Toronto 1
Uberlândia 1
Várzea Paulista 1
Woodbridge 1
Wuxi 1
Xanxerê 1
Yerevan 1
Totale 355
Nome #
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 77
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 75
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 72
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 59
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 56
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 49
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study 48
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 44
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 44
Totale 524
Categoria #
all - tutte 3.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.254


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202293 0 0 21 18 15 2 0 10 4 1 17 5
2022/2023124 17 17 4 15 7 19 6 7 21 0 8 3
2023/2024105 6 16 8 10 7 39 0 6 0 3 4 6
2024/2025202 5 5 11 10 13 9 10 8 27 51 43 10
Totale 524